This inventor holds 10 USPTO granted patents and 1 published patent application. Top assignees: Oxford Biomedica (UK) Limited, Institute of Virology of the Slovak Academy of Sciences, Bayer Healthcare LLC. Active years: 1991-2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Oxford OX2 64J, GB (1991)
- Oxford OX2 7NB, GB (2010)
- Oxford, GB (1999 - 2014)
Company Filing History:
3 out of 53 
2 out of 18 
1 out of 789 Years Active: 1991-2014
Title: Adrian Llewllyn Harris: A Pioneer in Tumor Therapy Innovations
Introduction
Adrian Llewllyn Harris is a distinguished inventor based in Oxford, GB, known for his impactful contributions to cancer research. With a portfolio of eight patents to his name, Harris has focused on developing innovative therapeutic methods for enhancing responses to radiation in tumor therapy.
Latest Patents
Among his latest advancements is the patent for "Methods of enhancing the response to radiation in tumor therapy using anti-DLL4 antibodies." This disclosure outlines approaches for treating cancer, tumors, and neoplasias through the administration of ionizing radiation alongside anti-DLL4 antibodies or DLL4-binding fragments. Another significant patent involves the MN gene and protein, where he identified the binding site of the MN protein. This MN protein plays a crucial role in cell adhesion and the formation of intercellular contacts, offering therapeutic targets that could inhibit the growth of preneoplastic/neoplastic vertebrate cells expressing abnormally high levels of MN protein. His innovations also include vectors encoding MN-specific antibodies, which could facilitate targeted therapies against cancer.
Career Highlights
Harris has been affiliated with key organizations that enhance his contributions to the field. Notably, he has worked with Oxford Biomedica (UK) Limited and the Institute of Virology of the Slovak Academy of Sciences, where he has implemented his research findings into practical applications.
Collaborations
Throughout his career, Harris has collaborated with esteemed colleagues such as Peter John Ratcliffe and John David Firth. These partnerships have allowed for the synergistic exchange of ideas, propelling advancements in therapeutic methods targeting cancer treatment.
Conclusion
Adrian Llewllyn Harris stands as a notable figure in the world of cancer research and innovation. His patents not only showcase his inventiveness but also the potential to significantly impact therapeutic approaches for tumor therapies. With ongoing research and significant collaborations, Harris continues to pave the way for future advancements in this critical field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile